Global
The world is adapting to rapid changes in the healthcare and life sciences ecosystem which is increasingly getting digitised and moving towards a new phase of evolution- Healthcare 4.0 . The stakeholders are battling to build a sustainable base for affordable, inclusive and high quality healthcare. Global players in the industry cannot afford to ignore India. It will be the most populous in the world by 2050 and will make its mark as a growing market, potential competitor or partner in manufacturing and R&D, and as a location for clinical trials.
India
India’s Life Sciences Industry has traversed a successful journey in the past 50 years. From an era of import dependency in the pre-1970s, high-quality local players moved the country towards self-sufficiency in life sciences by the 1990s. Since then, world class capabilities have helped the Indian industry build a strong global presence.
In this journey, the industry has achieved several successes and has contributed significantly to the Indian economy and healthcare outcomes, in both India and abroad. The sector in India has reached a level of maturity and offers the following advantages and opportunities.
- $1.3 billion domestic market
- Rise in income levels and growth in the size of middle class (12% to 28%)
- Highest USFDA facilities outside the United States
- Expanding health insurance coverage (300 Million to 655 Million)
- Increase in number of hospital beds from 1.6 Million to 2.9 Million
- Increase in FDI investments under automatic route
- Already a proven destination as a regional and global hub for large life sciences companies
- Manufacturing costs are 65% lower than US and 50% lower than Europe
- 20% of all ANDA to the FDA are expected to be filed by Indian companies
- Increased focus on innovation- 3,500 product patents in the last 5 years
- Lower cost of R&D talent, facilities and testing
- Large talent pool
Telangana- A $50 Billion Life Sciences Ecosystem
Telangana, the 29th and newest state of India, has been ranked #1 in ease of doing business in India and has come to be globally known for it’s commitment to a graft-free administration and zero tolerance for corruption
Telangana holds a dominant position in Life Sciences sector and has emerged as the pharma capital of the Country contributing to about 1/3rd of the pharmaceutical production
- Over 600 pharma and 200 biotech companies with combined value of $50 Billion. This is expected to reach $100 Billion by 2028
- India’s first and the largest life sciences cluster called Genome valley
- 1 in 3 vaccines exported globally from India, are manufactured in Hyderabad
- State sponsored skill-development programmes
- Best healthcare infrastructure in the country with about 50 public and 165 private hospitals, 4,000 clinics and nursing homes, and 500 diagnostic centres
A detailed document on the Telangana Government policy for the sector can be accessed at
Life Sciences Policy for the State of Telangana (2015-2020)
Leveraging the state’s leadership position in the Pharma sector, Government of Telangana is developing Hyderabad Pharma City in an area of 14,000 acres, which will be the largest and first of its kind, smart ecosystem creating a new international benchmark for Sustainable Industrial Cities.
Situated just about 25 KMs from the Hyderabad International airport, the cluster will provide centralized smart infrastructure solutions for R & D and manufacturing units.
Genome Valley
Genome Valley has emerged as the preferred destination for major R&D focused life sciences companies, in India. It houses over 150 Companies, making it the country’s largest cluster of multi-tenanted lab space infrastructure in a single location. Located in Shameerpet – Hyderabad, Genome Valley is a perfect blend of knowledge parks, special economic zones, multi-tenanted wet laboratories, incubation facilities, office spaces along with outstanding support facilities.
Genome Valley – India’s first systematically developed R&D cluster
In addition, the state has also set up a medical devices park at Sultanpur near Hyderabad to host a wide range of manufacturing units in this sector. The park will have an MoU with China Medical City located at Taizhou and another Medical Devices Park located in Gwangju in South Korea, to exchange knowledge with them. Over 14 companies have already initiated the process of setting up their units in this facility.
